Quality of life assessment in a chemoprevention trial: Fenretinide and oral or transdermal HRT

Maturitas

Volumn 55, Issue 1, 2006, Pages 69-75

  Serrano, Davide ^a   Mariani, Luigi ^a,d   Mora, Serena ^a   Guerrieri Gonzaga, Aliana ^a   Cazzaniga, Massimiliano ^a   Daldoss, Cristina ^b   Ramazzotto, Francesca ^b   Feroce, Irene ^a   Decensi, Andrea ^a,c   Bonanni, Bernardo ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c GALLIERA HOSPITAL   (Italy)

^d Biotechnology Section   (Italy)

Author keywords

Breast neoplasms; Chemoprevention; Estrogen replacement therapy; Fenretinide; Menopause symptoms and quality of life

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; FENRETINIDE; MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; ARTICLE; CARDIOVASCULAR SYSTEM; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VALIDATION PROCESS;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FENRETINIDE; HOT FLASHES; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MEDROXYPROGESTERONE ACETATE; MENOPAUSE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EQUIDAE;

EID: 33746266622     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2006.01.005     Document Type: Article

References (23)

1. Beral V., Banks E., and Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360 (2002) 942-944
2. Hilditch J.R., Lewis J., Peter A., et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 24 (1996) 161-175
3. Decensi A., Bonanni B., Baglietto L., et al. A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers. Clin Cancer Res 10 (2004) 4389-4397
4. Decensi A., Omodei U., Robertson C., et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 106 (2002) 1224-1228
5. Scarabin P.Y., Oger E., and Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362 (2003) 428-432
6. Perera M., Sattar N., Petrie J.R., et al. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study. J Clin Endocrinol Metab 86 (2001) 1140-1143
7. Veronesi U., De Palo G., Marubini E., et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91 (1999) 1847-1856
8. Decensi A., Torrisi R., Polizzi A., et al. Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface. J Natl Cancer Inst 86 (1994) 105-110
9. Cancer Therapy Evaluation Program. Common toxicity criteria, version 2.0. Bethesda (MD): National Cancer Institute, 30 April, 1999.
10. Stampfer M.J., Colditz G.A., Willett W.C., et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 325 (1991) 756-762
11. Grodstein F., Stampfer M.J., Falkeborn M., Naessen T., and Persson I. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology 10 (1999) 476-480
12. Mendelsohn M.E., and Karas R.H. The protective effects of estrogen on the cardiovascular system. N Engl J Med 340 (1999) 1801-1811
13. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
14. Simon J.A., Hsia J., Cauley J.A., et al. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation 103 (2001) 638-642
15. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
16. The menopausal transition: a different view. Proceedings of an international symposium. Leiden, The Netherlands, 18-19 June 1997. J Psychosom Obstet Gynaecol 1997;18:59-188.
17. Gelfand M.M., Moreau M., Ayotte N.J., Hilditch J.R., Wong B.A., and Lau C.Y. Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: a placebo-controlled study. Menopause 10 (2003) 29-36
18. Gambacciani M., Ciaponi M., Cappagli B., et al. Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas 44 (2003) 157-163
19. Fournier A., Berrino F., Riboli E., Avenel V., and Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114 (2005) 448-454
20. Greendale G.A., Lee N.P., and Arriola E.R. The menopause. Lancet 353 (1999) 571-580
21. Hilditch J.R., Lewis J., Ross A.H., et al. A comparison of the effects of oral conjugated equine estrogen and transdermal estradiol-17 beta combined with an oral progestin on quality of life in postmenopausal women. Maturitas 24 (1996) 177-184
22. Hlatky M.A., Boothroyd D., Vittinghoff E., Sharp P., and Whooley M.A. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 287 (2002) 591-597
23. Hays J., Ockene J.K., Brunner R.L., et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348 (2003) 1839-1854